Healthcare
Live Price
Offline$7.60
+0.00% today
Window Change
+11.27%
Window
Jun 20, 2025 → May 15, 2026
Coverage: 228 bars · Jun 20, 2025 → May 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Shanghai Pharmaceuticals Holding Co., Ltd (SHPMY) is a Healthcare stock with a market cap of $63.38B and listed on OTC. The stock last traded around $7.60 and up 11.3% across the available one-year price window (Jun 20, 2025 → May 15, 2026). Baseline metrics include revenue growth of +3.0%, EPS growth of +25.2%, a dividend yield of 2.4%. What stands out right now is revenue +3.0%, EPS +25.2%, free cash flow +11.7% with operating margin 3.5% and ROIC 4.6%. The dividend is present but secondary, with a yield around 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 10.9 and price/sales 0.2. Stock Foundry combines SHPMY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SHPMY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SHPMY Max Drawdown
-14.82%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SHPMY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$215.8B
-7.0% YoY
FY Net Income
$5.1B
-9.3% YoY
Free Cash Flow
$942.6M
-54.2% YoY
Revenue Growth
+3.0%
EPS Growth
+25.2%
Gross Margin
10.8%
Net Margin
2.0%
Income statement
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 283.6B | 275.3B | 260.3B | 232.0B | 215.8B |
| Gross Profit | 30.4B | 30.6B | 31.3B | 30.5B | 28.5B |
| Operating Income | 9.9B | 8.1B | 7.7B | 9.0B | 8.2B |
| EBITDA | 14.4B | 12.1B | 10.9B | 12.4B | 11.3B |
| Net Income | 5.7B | 4.6B | 3.8B | 5.6B | 5.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CNY
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.7B | 35.7B | 30.5B | 27.4B | 22.4B |
| Total Assets | 233.1B | 221.2B | 212.0B | 198.1B | 163.4B |
| Total Liabilities | 143.4B | 137.5B | 131.6B | 120.1B | 104.4B |
| Shareholder Equity | 75.9B | 71.7B | 68.5B | 67.1B | 49.4B |
| Total Debt | 49.5B | 47.8B | 42.9B | 38.6B | 31.7B |
| Net Debt | 16.8B | 12.0B | 12.4B | 11.2B | 9.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5.1B
+6.7% YoY
Capital Expenditures
4.1B
-53.4% YoY
Free Cash Flow
943M
-54.2% YoY
Key ratios
Gross Margin
10.8%
Operating Margin
3.5%
Net Margin
2.0%
ROE
7.6%
Debt / Equity
0.81x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.